TY - JOUR T1 - Impact of COVID-19 Attributable Deaths on Longevity, Premature Mortality and DALY: Estimates of USA, Italy, Sweden and Germany JF - medRxiv DO - 10.1101/2020.07.06.20147009 SP - 2020.07.06.20147009 AU - Sanjay K Mohanty AU - Manisha Dubey AU - Udaya S Mishra AU - Umakanta Sahoo Y1 - 2020/01/01 UR - http://medrxiv.org/content/early/2020/07/07/2020.07.06.20147009.abstract N2 - In a short span of four months, the COVID-19 pandemic has added over 0.4 million deaths worldwide, which are untimely, premature and unwarranted. The USA, Italy, Germany and Sweden are four worst affected countries, accounting to over 40% of COVID-19 deaths globally. The main objective of this study is to examine the impact of COVID-19 attributable deaths on longevity, years of potential life lost (YPLL) and disability adjusted life years (DALY) in USA, Italy, Germany and Sweden. Data from United Nation Population Projection, Statista and centre for disease control and prevention were used in the analyses. Life expectancy, YPLL and DALY were estimated under four scenarios; no COVID-19 deaths, actual number of COVID-19 death as of 22nd May, 2020 and anticipating COVID-19 death share of 6% and 10% respectively. The COVID-19 attributable deaths have lowered the life expectancy by 0.4 years each in USA and Sweden, 0.5 years in Italy and 0.1 years in Germany. The loss of YPLL was 1.5, 0.5, 0.1 and 0.5 million in USA, Italy, Germany and Sweden respectively. The DALY (per 1000 population) due to COVID-19 was 4 in USA, 6 in Italy, 1 each in Germany and Sweden. Compression in life expectancy and increase in YPLL and DALY may intensify further if death continues to soar. COVID-19 has a marked impact on mortality. Reduction in longevity premature mortality and loss of DALY is higher among elderly.Competing Interest StatementThe authors have declared no competing interest.Funding StatementNo financial disclosures were reported by the authors of this paper. Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study does not involve human participation. It used secondary data available in public domain and research ethics approval not required.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).Yes I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data from United Nation Population Projection, worldmeter.info, Statista and Centre for disease control and Prevention has been collected for analyses. https://population.un.org/wpp/DataQuery/ https://data.cdc.gov/NCHS/Provisional-COVID-19-Death-Counts-by-Sex-Age-and-S/9bhg-hcku/data https://www.statista.com/statistics/1105061/coronavirus-deaths-by-region-in-italy/ https://www.statista.com/statistics/1105512/coronavirus-covid-19-deaths-by-gender-germany). https://www.statista.com/statistics/1107913/number-of-coronavirus-deaths-in-sweden-by-age-groups; https://www.worldometers.info/coronavirus/ ER -